
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Bioclinica has announced that is has assembled a team of experts dedicated to nonalcoholic fatty liver disease and nonalcoholic steatohepatitis to help sponsors develop therapeutics using medical imaging and other biomarkers in clinical trials.
Read more about it






